163 related articles for article (PubMed ID: 37041169)
1. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors.
Zhang X; Wang Y; Zhang X; Shen Y; Yang K; Ma Q; Qiao Y; Shi J; Wang Y; Xu L; Yang B; Ge G; Hu L; Kong X; Yang C; Chen Y; Ding J; Meng L
Signal Transduct Target Ther; 2023 Apr; 8(1):153. PubMed ID: 37041169
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.
Xing H; Gao M; Wang Y; Zhang X; Shi J; Wang X; Liu X; Ma Q; Kong X; Yang C; Ding J; Meng L
Clin Transl Med; 2022 May; 12(5):e835. PubMed ID: 35604910
[TBL] [Abstract][Full Text] [Related]
3. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
Wang Y; Li X; Liu X; Chen Y; Yang C; Tan C; Wang B; Sun Y; Zhang X; Gao Y; Ding J; Meng L
Cancer Biol Med; 2019 Feb; 16(1):66-83. PubMed ID: 31119047
[TBL] [Abstract][Full Text] [Related]
5. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Wang YX; Zhang X; Ma QY; Hu LD; Zhang X; Wang Y; Xu L; Yang CH; Tan C; Kong XY; Ding J; Meng LH
Cell Death Dis; 2021 Jan; 12(1):85. PubMed ID: 33446653
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
8. [FAT1 inhibits cell proliferation of esophageal squamous cell carcinoma through regulating the expression of CDK4/CDK6/CCND1 complex].
Hu XL; Zhai YF; Li GD; Xing JF; Yang J; Bi YH; Wang J; Shi RY
Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):14-20. PubMed ID: 29365412
[No Abstract] [Full Text] [Related]
9. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
10. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
[TBL] [Abstract][Full Text] [Related]
12. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines.
Ma J; Guo X; Zhang S; Liu H; Lu J; Dong Z; Liu K; Ming L
Mol Med Rep; 2015 Jun; 11(6):4525-31. PubMed ID: 25634603
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
15. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
[TBL] [Abstract][Full Text] [Related]
16. XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.
Jian J; Li S; Liu LZ; Zhen L; Yao L; Gan LH; Huang YQ; Fang N
Int J Mol Med; 2020 Jul; 46(1):201-210. PubMed ID: 32377720
[TBL] [Abstract][Full Text] [Related]
17. PAQR3 overexpression suppresses the aggressive phenotype of esophageal squamous cell carcinoma cells via inhibition of ERK signaling.
Bai G; Chu J; Eli M; Bao Y; Wen H
Biomed Pharmacother; 2017 Oct; 94():813-819. PubMed ID: 28802234
[TBL] [Abstract][Full Text] [Related]
18. CDK11
Du Y; Yan D; Yuan Y; Xu J; Wang S; Yang Z; Cheng W; Tian X; Kan Q
Cell Cycle; 2019 Feb; 18(4):452-466. PubMed ID: 30722725
[TBL] [Abstract][Full Text] [Related]
19. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixidó C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
Cancer Cell; 2015 Apr; 27(4):533-46. PubMed ID: 25873175
[TBL] [Abstract][Full Text] [Related]
20. α-Hederin Induces Apoptosis of Esophageal Squamous Cell Carcinoma via an Oxidative and Mitochondrial-Dependent Pathway.
Wang J; Wu D; Zhang J; Liu H; Wu J; Dong W
Dig Dis Sci; 2019 Dec; 64(12):3528-3538. PubMed ID: 31273592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
